RxDoctor Payments Data

Christopher Mai, MD

Nephrology · New Smyrna Beach, FLNPI 1518957596

Payments from drug & device makers

$2,272in general payments, 2019–2025

Across 134 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Otsuka America Pharmaceutical, Inc.$170
  • AstraZeneca$157
  • Amarin Pharma, Inc.$139
  • OPKO Pharmaceuticals, LLC$129
  • Calliditas Therapeutics US Inc.$67
  • plus $577 from 21 others

What the payments were for

  • Food & beverage$2,16495%
  • Education$1085%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,272 in reported general payments places this provider in the 55th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$411,656
Medicare patients
747
Services billed
2,785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol707$727,638
OzempicSemaglutide177$206,849
JardianceEmpagliflozin86$119,294
MounjaroTirzepatide45$52,902
EliquisApixaban32$44,532
RybelsusSemaglutide13$32,374
Repatha SureclickEvolocumab24$23,936
Calcitriol980$21,890
EntrestoSacubitril/Valsartan21$18,690
AranespDarbepoetin Alfa In Polysorbat17$18,219
DapagliflozinDapagliflozin Propanediol38$17,754
TrulicityDulaglutide12$16,659
Bumetanide384$15,350
Irbesartan598$13,334
Nifedipine ErNifedipine283$12,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$157$727,638707 claims
Novo NordiskOzempic, Rybelsus$19$239,223190 claims
Lilly USA, LLCMounjaro, Trulicity$24$69,56157 claims
NovartisEntresto$41$18,69021 claims
AmgenAranesp$1,032$18,21917 claims
Arbor Pharmaceuticals, Inc.Edarbi$11$7,82521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 756 nephrology providers in Florida.

Other nephrology in New Smyrna Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →